Middle East Pharmaceutical Industries Co. Announces the Results of the Extraordinary General Assembly’s Meeting Included the Approval of the Company’s Capital Increase. (First Meeting)

Element List	Explanation
Introduction	The Board of Directors of Middle East Pharmaceutical Industries Company is pleased to announce the results of the Extraordinary General Assembly Meeting, which included the approval of the Company’s capital increase.
City and Location of the Extraordinary General Assembly's Meeting	Riyadh, Middle East Pharmaceutical Industries Co Headquarter - Via modern technology means. (Online)
Date of the Extraordinary General Assembly's Meeting	2026-05-11 Corresponding to 1447-11-24
Time of the General Assembly’s Meeting	18:30
Percentage of Attending Shareholders	69.41
Names of the Board of Directors' Members Present at the General Assembly's Meeting and Names of the Absentees	The following board members attended the meeting:

1- Mr. Ahmad Shaher AlTabbaa

2- Mr. Hisham Mohammed Attar

3- Mr. Alexander Triebnigg

4- Mr. Omar Mohammed AlJaroudi

5- Mr. Mohamed Maher AlGhannam Names of the Chairmen of the Committees Present at the General Assembly's Meeting or Names of Those Attending on their Behalf The following Committees’ Chairmen attended the Meeting:

1- Mr. Faisal Sulaiman AlJamaan

(Audit Committee Chairman).

2- Mr. Omar Mohammed AlJaroudi

(Nomination and Remuneration Committee Chairman). Voting Results on the Items of the General Assembly's Meeting Agenda's Attached. Additional Information No Attached Documents

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.